International Adaptive Trial Comparing Multiple Treatments for Staphylococcus Aureus Bloodstream Infection to Reduce Death Within 90 Days
Led by University of Melbourne · Updated on 2026-05-06
8000
Participants Needed
161
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
The trial investigates treatments for bloodstream infection caused by Staphylococcus aureus SAB, which can be life-threatening with a 15-30% death rate within three months. This international, multi-center randomized adaptive platform trial aims to find the best treatment options to reduce mortality within 90 days of infection. The trial adapts over time by assigning more patients to treatments that show better outcomes and removing less effective options.
Participants receive various antibiotic treatments depending on their group. These include intravenous vancomycin or daptomycin, flucloxacillin or cloxacillin, cefazolin, or benzylpenicillin, with dosages adjusted for kidney function or illness severity. Some receive adjunctive drugs like clindamycin, and others may switch from intravenous to oral antibiotics if eligible after 7 or 14 days. Additionally, some participants undergo PETCT scans as part of the study.
During the study, participants are monitored closely with blood cultures, temperature checks, and clinical assessments to track infection clearance and complications. Researchers measure all-cause mortality at 90 days as the primary outcome, along with other outcomes such as survival at earlier time points, hospital stay length, microbiological treatment failure, serious reactions, and antibiotic use. Safety and health economic data are also collected to evaluate treatments comprehensively throughout the trial.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Backbone therapy plus adjunctive intervention (e.g., beta‑lactam, PET/CT, oral switch)
Backbone antibiotic therapy alone
Guideline‑recommended antibiotic therapy for SAB
What it is
Backbone antibiotic therapy plus an adjunctive strategy such as adding a beta‑lactam, early switch to oral antibiotics, or PET/CT imaging
Backbone antibiotic therapy (e.g. vancomycin, cefazolin, flucloxacillin, or benzylpenicillin as appropriate to resistance profile) without any adjunctive intervention
Current guideline‑recommended antibiotic treatment for SAB based on organism susceptibility (anti‑staphylococcal beta‑lactams for MSSA/PSSA; vancomycin or alternatives for MRSA)
Role in trial
Investigational arm evaluating adjunctive strategies added to backbone therapy
Serves as control arm with standard backbone antibiotic therapy
Reflects current standard SAB antibiotic management, not part of trial randomization
Primary use
Treat SAB with backbone plus adjunctive component under investigation
Treat Staphylococcus aureus bacteremia with backbone antibiotics only
Treat SAB using guideline‑recommended antibiotic choice based on susceptibility
How it is given or performed
Backbone therapy as above plus randomized adjunctive intervention such as additional drug, imaging, or early oral switch
Administered intravenously per standard hospital protocols according to organism susceptibility
Administered intravenously, selecting beta‑lactam or vancomycin/daptomycin per pathogen susceptibility
Evidence status
Efficacy is under investigation; evidence not yet established
Supported by established clinical evidence for SAB management
Guideline‑recommended antibiotics are supported by consensus and laboratory evidence but new consensus guidance formalizes risk‑stratified management
Important risks
Additional risks may arise from adjunctive beta‑lactam exposure, imaging procedures, or oral switch mismatches
Risks include standard antibiotic‑associated toxicities such as nephrotoxicity, allergy, and treatment failure
Risks similar to backbone therapy, including beta‑lactam or vancomycin toxicity and allergy
Important limitations
Complex intervention makes it difficult to isolate effect of individual adjunctive components
May miss potential benefit of adjunctive strategies that could improve outcomes
Guideline consensus may lag new trial outcomes; real‑world applicability may vary by resource setting
Patient impact
Patient impact is uncertain until trial results are available
Uses established therapy with known patient outcomes
Guideline use aligned with consensus‑based management shown to standardize care
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
All Ages
All Genders
Eligibility Criteria
You may qualify if you...
Staphylococcus aureus grown from at least one blood culture
Admitted to a participating hospital at time of eligibility assessment or if deceased, admitted to the site from blood culture collection until assessment
Eligible for sub-studies if criteria met
For adjunctive treatment domain, eligible regardless of clindamycin susceptibility
For PSSA and MSSA treatment domains, confirmed susceptibility as per microbiology guidelines
For MRSA domain, confirmed MRSA infection
Eligibility for early oral switch domain requires infection clearance, afebrile status, source control, and no metastatic foci as per timing criteria
For PET/CT domain, patient must be accessible and eligible at participating site
You will not qualify if you...
More than 72 hours elapsed since index blood culture collection
Polymicrobial bacteraemia with multiple organisms (excluding contaminants)
Previous participation in randomized SNAP platform
Positive blood culture for same S. aureus type within past 72 hours to 180 days
Treating team deems study enrollment not in patient's best interest or death imminent
Patient receiving end-of-life care or under 18 at sites without pediatric approval
Patient deceased since blood culture collection
Hypersensitivity or severe allergy to study antibiotics
Currently receiving clindamycin or linezolid that cannot be stopped when applicable
Necrotising fasciitis or current severe diarrhea including C. difficile associated diarrhea
Presence of prosthetic cardiac devices or intravascular infections for early oral switch domain
Pregnancy or breastfeeding for PET/CT domain
Clinical instability or contraindications for PET/CT scan
Inability to adhere to oral therapy or unreliable gastrointestinal absorption when applicable
Ongoing systemic antibacterial treatment incompatible with trial therapies when applicable
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 90 days from randomisation
Participants receive assigned antibiotic treatments intravenously or orally as part of routine care. Treatment options include various antibiotics and may include adjunctive therapies based on infection type and eligibility.
Visits and treatment administration occur according to usual hospital care and trial schedule, including assessments at Day 7 (+/- 2 days) and Day 14 (+/- 2 days) for eligibility and treatment modifications
Follow-up
Duration - Up to 90 days after randomisation
Participants are monitored for outcomes including survival, infection resolution, adverse reactions, and functional recovery for up to 90 days after starting treatment.
Follow-up visits and assessments occur periodically during the 90-day period
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
12
Similar Trials
Studying Combination versus Single Antibiotic Treatment for Staphylococcus Aureus Bloodstream Infection in Hospitalized Adults
Evaluating Cefazolin Combined With Ertapenem Versus Placebo for Treatment of Methicillin-Susceptible Staphylococcus Aureus Bacteremia
Comparing Dabigatran and Oral Anti-Xa Inhibitors for Treatment of Staphylococcus aureus Bloodstream Infection
Comparison of Daptomycin and Vancomycin Injections for Treating MRSA Bloodstream Infection
International Adaptive Trial Comparing Multiple Treatments for Staphylococcus Aureus Bloodstream Infection to Reduce Death Within 90 Days
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial.
Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group
Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol.
A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial.
Robert K Mahar, Anna McGlothlin, Michael Dymock...